5-HTP Sleep Meta-analysis: What the Evidence Says

Quick Answer

5-HTP Sleep Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Excessive daytime sleepiness (EDS) describes a reduced ability to stay awake during the day. [Li Jingqi (2025); evidence level 1]
• In particular, rapid eye movement (REM) sleep behavior disorder (RBD), a condition involving dream-enacting movements during sleep, is associated with early brain changes and the accumulation of α-synuclein in locus coeruleus and thalamus. [Li Jingqi (2025); evidence level 1]
• The etiology of fatigue in IBD is multifactorial and may be associated with inflammation, anemia, nutrient deficiencies, medications, and microbiota. [MORAIS Tayane (2026); evidence level 4]
• Fatigue in patients with IBD is associated with decreased physical functioning, mood disturbances, and low productivity, presenting symptoms of physical and mental exhaustion. [MORAIS Tayane (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For 5-HTP sleep meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Li Jingqi (2025). Sleep disorders in Parkinson’s disease: evaluating pharmacological treatments through systematic review and meta-analysis. DOI: 10.1186/s12883-025-04526-5. PMCID: PMC12706981. PMID: 41398241. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12706981/
• MORAIS Tayane (2026). PHARMACOLOGICAL TREATMENTS FOR FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTEGRATIVE REVIEW. DOI: 10.1590/S0004-2803.24612025-081. PMCID: PMC12788763. PMID: 41538673. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12788763/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.